Jonathan Schimmel1, Alex F Manini2. 1. Division of Medical Toxicology, Dept of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 2. Division of Medical Toxicology, Dept of Emergency Medicine, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, New York, New York, USA.
Abstract
BACKGROUND: Alarms have been raised that COVID-19 may disproportionately affect certain populations with substance use disorders, particularly Opioid Use Disorder (OUD), however warnings have largely focused on social risks such as reduced availability of services. Objectives: This commentary highlights three plausible biological mechanisms for potentially worsened outcomes in patients with OUD who contract COVID-19. Results: Opioid-related respiratory depression may amplify risks of hypoxemia from COVID-19 viral pneumonia. Complex opioid immune modulation may impact host response to COVID-19, though the effect direction and clinical significance are unclear. Drug-drug interactions may affect individuals with OUD who are co-administered medications for OUD and medications for COVID-19, particularly due to cardiac adverse effects. Conclusions/Importance: There are plausible biological mechanisms for potentially worsened outcomes in patients with OUD who contract COVID-19; these mechanisms require further study, and should be considered in individuals with OUD.
BACKGROUND: Alarms have been raised that COVID-19 may disproportionately affect certain populations with substance use disorders, particularly Opioid Use Disorder (OUD), however warnings have largely focused on social risks such as reduced availability of services. Objectives: This commentary highlights three plausible biological mechanisms for potentially worsened outcomes in patients with OUD who contract COVID-19. Results: Opioid-related respiratory depression may amplify risks of hypoxemia from COVID-19 viral pneumonia. Complex opioid immune modulation may impact host response to COVID-19, though the effect direction and clinical significance are unclear. Drug-drug interactions may affect individuals with OUD who are co-administered medications for OUD and medications for COVID-19, particularly due to cardiac adverse effects. Conclusions/Importance: There are plausible biological mechanisms for potentially worsened outcomes in patients with OUD who contract COVID-19; these mechanisms require further study, and should be considered in individuals with OUD.
Entities:
Keywords:
COVID; OUD; Opioid Use Disorder; coronavirus; risk factors
Authors: Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos Journal: JAMA Date: 2020-05-26 Impact factor: 56.272
Authors: Fares Qeadan; Benjamin Tingey; Rona Bern; Christina A Porucznik; Kevin English; Ali I Saeed; Erin Fanning Madden Journal: EClinicalMedicine Date: 2021-06-04
Authors: Colleen B Mistler; Christine M Curley; Aviana O Rosen; Renee El-Krab; Jeffrey A Wickersham; Michael M Copenhaver; Antoine Khati; Roman Shrestha Journal: J Community Health Date: 2021-03-26
Authors: Étienne Meunier; Anne E Sundelson; Stephen Tellone; Daniel Alohan; Celia B Fisher; Christian Grov Journal: J Urban Health Date: 2021-05-04 Impact factor: 3.671
Authors: Colleen B Mistler; Matthew C Sullivan; Michael M Copenhaver; Jaimie P Meyer; Alexis M Roth; Sheela V Shenoi; E Jennifer Edelman; Jeffrey A Wickersham; Roman Shrestha Journal: J Subst Abuse Treat Date: 2021-04-08